<h4>Background</h4>Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that has proven efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.